Latest news from AKIGAI

BRUSSELS - HERE WE COME !

AKIGAI has been invited to the EIC Accelerator grant interview in Brussels next month.

FDA grants Orphan Designation for the treatment of CRPS with AKI-007

Dramatic, durable and safe pain relief in chronic CRPS patients has lead to this milestone. A phase III trial is the next step.

Orphan Designation

AKIGAI is excited that we were granted an Orphan Designation from the EMA for the treatment of CRPS with our 1st generation EGFR inhibitor tablet.